Cronos Group Inc vs McCormick & Company, Incorporated — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.20B), while McCormick & Company, Incorporated trades at $45.94 (market cap $12.20B). The key difference: McCormick & Company, Incorporated is far larger — about 10.2× Cronos Group Inc's market cap, and McCormick & Company, Incorporated pays a 4.24% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and McCormick & Company, Incorporated for 67 Days on average.
| CRON | MKC | |
|---|---|---|
Market Cap | $1.20B | $12.20B |
Volume | 450,387 | 4,117,008 |
Sector | Health | Consumer Staples |
52-Week High | $3.55 | $71.65 |
52-Week Low | $2.30 | $44.14 |
Typical Hold Time | 22 Days | 67 Days |
Enterprise Value | $401.73M | $16.88B |
Dividend Yield | — | 4.24% |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 1.98% on the day, amid a bearish technical signal. The company reported mixed quarterly earnings but achieved record revenue and gross profit in Q2 2026, with net income turning positive. Recent investor day highlighted international expansion and cash flow focus. Valuation ratios show a P/E of 17.11 and P/S of 6.91, with strong net income margin of 39.08% projected for 2026.
Outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but risks include cash flow volatility and competitive pressures. Analyst consensus is mixed with 60% hold rating. The stock's near-term performance hinges on execution of expansion plans and sustained earnings momentum.
MKC trades at $45.94, up 1.19% today, with a bearish technical signal but strong fundamentals. Recent Q3 2026 earnings beat estimates with $0.86 EPS, driven by 17% sales growth and margin expansion. The stock appears undervalued with a P/E of 8.18 and offers a dividend yield. Cash flow trends show operational strength despite a net outflow in 2025.
The outlook is mixed: solid earnings growth and a $53.50 consensus price target suggest upside, but technical weakness and competitive pressures pose risks. Investor sentiment is cautious with a 'Hold' analyst consensus. Key catalysts include continued margin improvement and integration of recent acquisitions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →